MARKET

MESO

MESO

Mesoblast
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.87
-0.30
-4.86%
After Hours: 5.88 +0.01 +0.17% 16:13 09/20 EDT
OPEN
6.03
PREV CLOSE
6.17
HIGH
6.07
LOW
5.83
VOLUME
208.33K
TURNOVER
--
52 WEEK HIGH
19.45
52 WEEK LOW
5.83
MARKET CAP
761.57M
P/E (TTM)
-6.1305
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
Hot Stocks: LCID's PIPE nightmare; Oil-related stocks suffer; PVH hits high; MESO drops again; PLAN rallies
The S&P 500 and the Nasdaq managed to eke out thin gains on Wednesday despite weakness in certain parts of the oil-production and refining sectors. Devon Energy (NYSE:DVN), Marathon Oil
Seekingalpha · 09/01 21:56
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday.
Benzinga · 09/01 16:00
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-19 diagnostic with Harvard's Wyss Institute.
Benzinga · 09/01 11:04
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
Mesoblast Limited (NASDAQ: MESO) shares dived on Tuesday as the FDA raised more questions around its flagship drug candidate, and its 
Benzinga · 08/31 16:10
33 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 08/31 16:05
Regional Health Properties, AC Immune leads healthcare gainers; RenovoRx, Poseida Therapeutics among major losers
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, Poseida Ther...
Seekingalpha · 08/31 15:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MESO. Analyze the recent business situations of Mesoblast through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MESO stock price target is 14.25 with a high estimate of 23.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 63
Institutional Holdings: 3.93M
% Owned: 3.03%
Shares Outstanding: 129.74M
TypeInstitutionsShares
Increased
18
1.37M
New
7
193.97K
Decreased
8
343.59K
Sold Out
10
62.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Swedish
Chief Executive Officer/Executive Director
Silviu Itescu
Vice Chairman/Non-Executive Independent Director
William Burns
Chief Financial Officer
Andrew Chaponnel
Chief Operating Officer
Dagmar Rosa - Bjorkeson
General Counsel
Peter Howard
Other
Fred Grossman
Other
Justin Horst
Other
Michael Schuster
Other
Paul Simmons
Other
Geraldine Storton
Non-Executive Independent Director
Philip Facchina
Non-Executive Independent Director
Donal O'Dwyer
Non-Executive Independent Director
Eric Rose
Non-Executive Independent Director
Michael Spooner
Non-Executive Independent Director
Shawn Tomasello
No Data
  • All
  • Financials
  • Insiders
More
About MESO
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.

Webull offers kinds of Mesoblast limited (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.